INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46h ago
HOUSE PTR6h ago
SEC 13F6h ago
ROBINHOOD CHAIN6h ago
Corporate insider
KD

Kerr Douglas

Chief Medical OfficerCIK 0001814189

EDGAR filingsOpen in network
Disclosed transactions5
Buys / sells0 / 3
Max Insider Score10
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
KD
Kerr DouglasHead of R&D and CMO
DYNDyne Therapeutics, Inc.
Grant or award
A—
8,000 sh
Oct 20, 2026Oct 22, 2026
traded Oct 20, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Dyne Therapeutics, Inc.Chief Medical Officer · Aug 17, 2026
5
KD
Kerr DouglasHead of R&D and CMO
DYNDyne Therapeutics, Inc.
Grant or award
A
—
12.0K sh
Oct 20, 2026
Oct 22, 2026
traded Oct 20, 2026
+2d
SEC FORM 4

Evidence

9
KD
Kerr DouglasChief Medical Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$91K
3,745 sh
Sep 4, 2026Sep 8, 2026
traded Sep 4, 2026
+4dSEC FORM 4

Evidence

6
KD
Kerr DouglasChief Medical Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$24K
1,290 sh
Sep 8, 2026Sep 8, 2026
traded Sep 8, 2026
+0dSEC FORM 4

Evidence

10
KD
Kerr DouglasChief Medical Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$41K
1,556 sh
Aug 13, 2026Aug 17, 2026
traded Aug 13, 2026
+4dSEC FORM 4

Evidence